$1,131.50
1.66% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US75886F1075
Symbol
REGN
Sector
Industry

Regeneron Pharmaceuticals Stock price

$1,131.50
+65.31 6.13% 1M
+159.40 16.40% 6M
+253.21 28.83% YTD
+313.11 38.26% 1Y
+451.93 66.50% 3Y
+839.50 287.50% 5Y
+783.40 225.05% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-19.06 1.66%
ISIN
US75886F1075
Symbol
REGN
Sector
Industry

Key metrics

Market capitalization $124.71b
Enterprise Value $117.60b
P/E (TTM) P/E ratio 29.96
EV/FCF (TTM) EV/FCF 35.33
EV/Sales (TTM) EV/Sales 8.72
P/S ratio (TTM) P/S ratio 9.25
P/B ratio (TTM) P/B ratio 4.42
Revenue growth (TTM) Revenue growth 6.46%
Revenue (TTM) Revenue $13.49b
EBIT (operating result TTM) EBIT $4.11b
Free Cash Flow (TTM) Free Cash Flow $3.33b
Cash position $9.82b
EPS (TTM) EPS $37.76
P/E forward 29.92
P/S forward 8.80
EV/Sales forward 8.30
Short interest 2.02%
Show more

Create a Free Account to create an Regeneron Pharmaceuticals alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Regeneron Pharmaceuticals Stock Analysis

Analyst Opinions

27 Analysts have issued a Regeneron Pharmaceuticals forecast:

20x Buy
74%
5x Hold
19%
2x Sell
7%

Analyst Opinions

27 Analysts have issued a Regeneron Pharmaceuticals forecast:

Buy
74%
Hold
19%
Sell
7%

Financial data from Regeneron Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
13,489 13,489
6% 6%
100%
- Direct Costs 2,320 2,320
10% 10%
17%
11,169 11,169
6% 6%
83%
- Selling and Administrative Expenses 2,368 2,368
19% 19%
18%
- Research and Development Expense 4,234 4,234
13% 13%
31%
4,567 4,567
5% 5%
34%
- Depreciation and Amortization 453 453
15% 15%
3%
EBIT (Operating Income) EBIT 4,114 4,114
7% 7%
30%
Net Profit 4,322 4,322
1% 1%
32%

In millions USD.

Don't miss a Thing! We will send you all news about Regeneron Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Regeneron Pharmaceuticals Stock News

Neutral
Seeking Alpha
2 days ago
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Wells Fargo 2024 Healthcare Conference September 5, 2024 12:45 PM ET Company Participants Marion McCourt - EVP, Commercial Ryan Crowe - SVP, IR and Strategic Analysis Conference Call Participants Mohit Bansal - Wells Fargo Mohit Bansal Great. So my name is Mohit Bansal, and thank you for the post lunch session.
Positive
The Motley Fool
2 days ago
Regeneron is an innovative drugmaker that continues to perform well. Shopify's changed and improved business should lead to stronger returns.
Neutral
Seeking Alpha
3 days ago
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 11:30 AM ET Company Participants Ryan Crowe - Senior Vice President, Investor Relations and Strategic Analysis Chris Fenimore - Senior Vice President, Finance and Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Great. Thanks f...
More Regeneron Pharmaceuticals News

Company Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Head office United States
CEO Leonard Schleifer
Employees 13,450
Founded 1988
Website www.regeneron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today